Human Papillomavirus Types 52 and 58 Are Prevalent in Uterine Cervical Squamous Lesions from Japanese Women by Takehara, Kazuhiro et al.
SAGE-HindawiAccess to Research
Pathology Research International
Volume 2011, Article ID 246936, 7 pages
doi:10.4061/2011/246936
Clinical Study
HumanPapillomavirus Types 52and 58ArePrevalent in Uterine
CervicalSquamous Lesionsfrom JapaneseWomen
Kazuhiro Takehara,1 Tamaki Toda,2 Toshinao Nishimura,2 Junichi Sakane,2
Yosuke Kawakami,1 Tomoya Mizunoe,1 Morie Nishiwaki,3 andKiyomiTaniyama4
1Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center,
Kure 737-0023, Japan
2Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center,
Kure 737-0023, Japan
3GLab Pathology Center Co., Ltd., Sapporo 060-0009, Japan
4Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure 737-0023,
Japan
Correspondence should be addressed to Kiyomi Taniyama, taniyamak@kure-nh.go.jp
Received 24 January 2011; Accepted 22 March 2011
Academic Editor: Nirag Jhala
Copyright © 2011 Kazuhiro Takehara et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. To estimatethe prevalence andgenotypes ofhigh-risk humanpapillomavirus(HPV) focusingHPV 16,18,52, and58in
Japan. Methods. Liquid-base cytology specimens were collected from Japanese women (n = 11022), aged 14–98. After classifying
cytodiagnosis,specimens were analyzed forHPVDNA by themultiplex polymerasechainreaction method, where 1195specimens
were positive forcervical smear, except adenomatous lesions.Result. HPV genotypes were detected in 9.5% of NILM and 72.2% of
ASC-US or more cervical lesions. In positive cervical smears, HPV genotypes were HPV 52 at 26.6%, HPV 16 at 25.2%, HPV 58
at 21.8%, and HPV 18 at 7.1%. Most patients infected with HPV 16 were between 20-29 years old, decreasing with age thereafter.
As for HPV 52 and 58, although the detection rate was high in 30- to 39-year-olds, it also was signiﬁcant in the 50s and 60s age
groups. Conclusion. In Japan, as a cause of abnormal cervical cytology, HPV52 and 58 are detected frequently in addition to HPV
16. In older age groups, HPV 52 and 58 detection rates were higher than that observed for HPV 16. After widespread current HPV
vaccination, we still must be aware of HPV 52 and 58 infections.
1.Introduction
Cervical cancer is the major cause of death from gyne-
cological cancer worldwide, even though screening with
cervical cytological testing (the Papanicolaou (Pap) test) has
been available for over 50 years. In recent years, molecular
biology has ﬁrmly established a causal relationship between
persistent infection with high-risk human papillomavirus
(HPV) genotypes and cervical cancer. Hence, geographic
variations in HPV type distributions should be an important
consideration [1]. A meta-analysis including 14 Japanese
studies revealed that high-risk types considered carcinogenic
or probably carcinogenic included HPV 16, 18, 31, 33, 35,
52, and 58 in Japan [2, 3]. Mu˜ noz et al. reported that HPV
16 and 18 were associated with 73.5% of invasive cervical
cancer (ICC) in Southeast Asia, 76.9% in Northern Africa,
and 71.5% in Europe/North America and HPV 52 and 58
were detected in 6.1% of ICC cases in Southeast Asia, 1.5%
in Northern Africa, and 1.1% in Europe/North America
[4]. In Japan, however, HPV 16 and 18 were less frequently
identiﬁed (58.8%) and HPV 52 and 58 were more common
(13.7%) [2].
Recently, we have started a new trial for liquid-based
cytology (LBC) with ThinPrep, in conjunction with a novel,
one-step HPV-typing method using multiplex polymerase
chainreactionmethod(PCR)inJapan(CCLBCstudy)under
the ﬁnancial support of the National Hospital Organization
of Japan. The CCLBC study has been designed to perform a2 Pathology Research International
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Figure 1: Objectives proﬁle number in the parenthesis: average age, range.
multihospital analysis to further assess the eﬀort of LBC and
the prevalence of HPV of the cervix.
In this paper, we report the prevalence of the HPV
genotypes focusing on HPV 16, 18, 52, and 58, using LBC
in Japan.
2.Materialsand Methods
This study was based on a CCLBC study. That is, cervical
cytology samples were obtained by a Broom Brush from
8 hospitals and institutes (Kure Medical Center/Chugoku
Cancer Center, JA Hiroshima General Hospital, Hiroshima-
Nishi Medical Center, Chugoku Central Hospital, Fukuyama
Medical Center, Fukuyama City Hospital, Aﬃliated Hos-
pitals of Clinical Laboratory for Fukuyama City Medical
Association, and Hamada Medical Center). To compare LBC
with the conventional Pap smear, a split-sample method was
employed.Cytologywasdiagnosed by themost severelesion,
as identiﬁed by LBC or the conventional Pap smear. Between
October 2007 and March 2010, 11022 specimens (9760
negative for intraepithelial lesion or malignancy (NILM),
1195 abnormal smear ﬁndings, except adenomatous lesions)
excluding inadequate specimens were available for analysis.
Written informed consent was obtained from all patients.
Pap-stained specimens were screened by cytotechnolo-
gists and were classiﬁed according to the Bethesda system
2001. All cytotechnologists and cytopathologists participat-
ing in the study had been authorized by Cytyc Corporation
for use of the ThinPrep test.
We randomly selected 2068 specimens from the 9760
samples of normal cytology. These 2068 normal cytology
specimens and 1195abnormal cytologyspecimens were used
for detecting HPV genotypes (Figure 1). The residual cells
i nt h ep r e s e r v a t i v em e d i u mw e r eu s e df o rt h ep r e p a r a t i o n
of DNA samples. HPV-DNA testing was performed using
themultiplex PCR method (PapiPlex) atthe GLab Pathology
Center Co., Ltd. (Sapporo, Japan). It can detect 16 high- and
low-risk HPV genotypes (genotypes 6, 11, 16, 18, 30, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) in a single tube.
Nishiwaki et al. provided more details about the multiplex
PCR method (PapiPlex) in their paper [5].
3.Results
This analysis included 11022 Japanese women. The mean
age of the study subjects was 44.6 years (range, 14–98
years). Of these, 9760 cases did not exhibit abnormal
cytological ﬁndings (NILM). ASC-US or more were found
in 1262 cervical smears. Of the total, 1195 were squamous
lesions (169 ASC-US, 25 atypical squamous cells, cannot
exclude high-grade squamous intraepithelial lesion (ASCH),
447 low-grade squamous intraepithelial lesion (LSIL), 449
high-grade squamous intraepithelial lesion (HSIL), and 105
squamous cell carcinoma (SCC)) and 67 were adenomatous
lesions. The age and distribution were almost the same in the
two groups (Table 1). There were 841 patients of abnormal
cytological ﬁndings, and 194 ofNILM were positive for HPV
genotyping. The mean age of HPV-positive patients with
abnormal squamous lesion was 37.9 years (range, 17–86
years), and that of patients with NILMwas 37.8 years (range,
15–83).
HPV prevalence was 9.4% in 2068 women with NILM,
45.6% (77/169) in ASC-US, 68.0% (17/22) in ASCH, 65.1%
(291/447) in LSIL, 83.3% (374/449) in HSIL, and 78.1%
(82/105) in SCC (Table 2).
In NILM, the detected HPV genotypes and positive rates
were HPV 52 (23.7%, 46/194), HPV 58 (17.0%, 33/194),
HPV 16 (15.5%, 30/194), HPV 18 (10.8%, 21/194), and
HPV 39 (10.3%, 20/194), in order of frequency. In abnormal
smear ﬁndings, HPV genotypes and positive rates were HPV
16 (27.5%, 231/841), HPV 52 (27.3%, 230/841), HPV 58
(26.9%, 193/841), HPV 51 (9.6%, 81/841), and HPV 31
(8.6%, 72/841), in order of frequency. HPV genotypes and
rates of SCC in HPV-positive cases were HPV 16 (16.9%,Pathology Research International 3
Table 1: Characteristics at registration of all patients.
Characteristic n = 11022 n = 2068
∗
Age
Mean (range) 44.6y (14–98y) 45.2y (15–98y)
10–19 years 123 (1.1%) 22 (1.1%)
20–29 years 1657 (15.0%) 331 (16.2%)
30–39 years 2658 (24.1%) 461 (22.5%)
40–49 years 2703 (24.5%) 537 (26.2%)
50–59 years 2108 (19.1%) 403 (19.7%)
60–69 years 1117 (10.1%) 197 (9.6%)
70–79 years 517 (4.7%) 91 (4.4%)
80–89 years 132 (1.2%) 23 (1.1%)
90–99 years 7 (0.1%) 3 (0.14%)
Symptoms
None 9859 1869
Bleeding 746 127
Others 414 71
Unknown 3 1
Cytodiagnosis (The Bethesda System 2001)
NILM 9760∗
Abnormal smear 1262
ASCUS 169
ASCH 25
LSIL 447
HSIL 449
SCC 105
Adenomatous lesions 67
An abnormal smear is deﬁned as one with atypical squamous cells of undetermined signiﬁcance (ASCUS) or more severe cytological ﬁndings.
∗2068 from 9760 NILM patients randomly assigned to detect HPV genotype.
44/261), HPV 18 (8.2%, 6/73), HPV 52 (7.6%, 21/276), and
HPV 58 (5.8%, 13/226), in order of frequency (Table 2).
In NILM, the prevalence of HPV 16, 18, 52, and 58
was high among the 20- to 39-year olds. HPV 16, 18, 52,
and 58 detection rates in HSIL or more severe cytological
ﬁndings were higher than those in women with cytological
abnormalities across all age groups. In HSIL or more, the
prevalence of HPV 16 was highest among women aged 20
to 29 years old, decreasing with age thereafter. As for HPV
52 and HPV 58, although the detection rate was high in 30-
to 39-year olds, it had increased in the 50s and 60s again
(Table 3, Figure 2).
4.Discussion
Recent studies revealed that at least 13 HPV types, including
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 are
commonly associated with ICC [4, 9–11]. While HPV 16 is
the most prevalent type in the world, it has been reported
that the frequency of other high-risk HPV types varies by
region. In this study, to investigate the prevalence of HPV
genotypesin Japan, especially HPV 52and 58,cervical smear
HPV-DNA testing was performed by a PCR method. For
adenomatouslesions, itsstatusas a precancerlesion hasbeen
uncertain, so we excluded it from this consideration. HPV
was detected in 9.4% of patients with NILM and in 70.4% of
patients with cytological abnormalities. In a meta-analysis,
the overall HPV prevalence in Japanese women with normal
cytology was only 10.2% [2]. Some previous studies have
shown the overall HPV prevalence in Japanese women with
normal cytology to be 9.7–22.5% (Table 4)[ 3, 6–8]. In the
present study, the mean age of normal cytology cases was
44.4 years and the mean age of HPV-positive cases was 37.8
years. Because HPV infection was most frequently detected
in young women aged 15–25 years, HPV detection rate was
considered to be high.
In abnormal smear cases, HPV genotypes and positivity
were HPV 16 at 27.5%, 52 at 27.3%, 58 at 26.9%, 51 at
9.6%, and 31 at 8.6%, in order of frequency. These data
indicate that these HPV subtypes mainly involve abnormal
cervical lesions. Miura et al. performed a meta-analysis of
H P Vt y p ep r e v a l e n c ea n dt y p e - s p e c i ﬁ cr i s k sf o rc e r v i c a l
carcinogenesis in Japan. They reported that 21 kinds of HPV
types were detected from invasive cervical cancer, where the
HPV genotypes and positive rates were HPV 16, 18, 52, 58,
33, 31, 35, and 51, in order of frequency [2]. Comparing
data with the pooled analysis of Mu˜ noz et al., they pointed
out that HPV 16 and 18 were less frequent and HPV 52
and 58 were more common in Japan. In this study, rates of
SCC in HPV-positive cases were HPV 16 at 16.9%, 18 at4 Pathology Research International
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Table 3: Prevalence of HPV and cytological ﬁndings by age.
(a) Women without cytological abnormalities (NILM)
HPV type 10–19
n = 22
20–29
n = 331
30–39
n = 461
40–49
n = 537
50–59
n = 403
60–69
n = 197
>70
n = 117
All
n = 2068
HPV 16 1 (4.5%) 7 (2.1%) 12 (2.6%) 8 (1.5%) 1 (0.2%) 0 1 (0.9%) 30 (1.5%)
HPV 18 1 (4.5%) 8 (2.4%) 6 (1.3%) 4 (0.7%) 1 (0.2%) 1 (0.5%) 0 21 (1.0%)
HPV 52 1 (4.5%) 15 (4.5%) 7 (1.5%) 8 (1.5%) 5 (1.3%) 7 (3.6%) 3 (2.6%) 46 (2.2%)
HPV 58 1 (4.5%) 10 (3.0%) 15 (3.3%) 4 (0.7%) 0 2 (1.0%) 1 (0.9%) 33 (1.6%)
(b) Women with cytological abnormalities
HPV type 10–19
n = 21
20–29
n = 271
30–39
n = 358
40–49
n = 290
50–59
n = 153
60–69
n = 69
>70
n = 33
All
n = 1195
HPV 16 3 (14.0%) 88 (32.5%) 69 (19.3%) 46 (15.9%) 15 (9.8%) 7 (10.1%) 3 (9.1%) 231 (19.3%)
HPV 18 3 (14.0%) 18 (6.6%) 15 (4.2%) 8 (2.8%) 6 (3.9%) 2 (2.9%) 0 52 (4.4%)
HPV 52 5 (23.8%) 62 (22.9%) 70 (19.6%) 48 (16.6%) 19 (12.4%) 20 (29.0%) 6 (18.2%) 230 (19.2%)
HPV 58 3 (14.0%) 56 (20.7%) 58 (16.2%) 37 (12.8%) 16 (10.5%) 20 (29.0%) 3 (9.1%) 193 (16.2%)
(c) Women with cytological abnormalities of HSIL or more
HPV type 10–19
n = 4
20–29
n = 127
30–39
n = 183
40–49
n = 117
50–59
n = 64
60–69
n = 41
>70
n = 18
All
n = 554
HPV 16 1 (25.0%) 59 (46.5%) 53 (29.0%) 36 (30.8%) 14 (21.9%) 4 (9.8%) 3 (16.7%) 170 (30.7%)
HPV 18 0 5 (3.9%) 10 (5.5%) 6 (5.1%) 5 (7.8%) 2 (4.9%) 0 28 (5.1%)
HPV 52 1 (25.0%) 29 (22.8%) 42 (23.0%) 28 (23.9%) 12 (18.8%) 13 (31.7%) 6 (33.3%) 131 (23.6%)
HPV 58 1 (25.0%) 31 (24.4%) 35 (19.1%) 17 (14.5%) 11 (17.2%) 12 (29.3%) 2 (11.1%) 109 (19.7%)
Table 4: Reports of HPV prevalence in cytologically normal women.
Author Year Number of patients Duration of sample collection Mean age (range) HPV prevalence
Yoshikawa et al. [6] 1999 130 1995–1996 40.7 (unknown) 14.6% (19/130)
Sasagawa et al. [7] 2001 1562 1995–1999 unknown (16–72) 9.7% (151/1562)
Asato et al. [8] 2004 3249 1993–1995 52.4 (18–85) 10.2% (333/3249)
Onuki et al. [3] 2009 1517 1999–2007 35.0 (15–78) 22.5% (342/1517)
Present report 2068 2007–2009 44.4 (15–98) 9.4% (194/2068)
8.2%, 52 at 7.6%, and 58 at 5.8%, in order of frequency.
These data indicate that HPV 16 and 18 are the major types
in all continents and HPV 52 and 58 are the commonest
types in Japan. Recently, Onuki et al. also reported that
HPV 16 and 18 were less frequently identiﬁed in ICC cases
in Japan compared with Southeast Asia, North America,
and Europe, with HPV 31, 33, 52, and 58 accounting for
approximately 20% of ICC [3]. For such reasons, a diﬀerent
strategy for HPV vaccination will be necessary in Japan,
although HPV 16 and 18 vaccines have been licensed since
2009. Onuki et al. suggested that HPV 16 and 18 vaccines
may provide 65% protection against ICC in Japan, which
is lower than the initial proposal that current HPV vaccines
which are directedagainst onlyHPV16andl8are considered
to prevent a majority (>70%) of cervical cancer world-wide
[12, 13]. The lower rate of eﬀectiveness arises from the fact
that HPV 16 and 18 are less frequently identiﬁed and HPV
31, 33, 52, and 58 are more common in ICC cases in Japan
compared to Southeast Asia, Northern Africa, Europe, and
North America.
Recently, the interpretation of geographical variations
of HPV type distribution has been requiring careful con-
sideration in view of the diﬀerences in sensitivity of the
HPV detection assays [1]. For example, it has been reported
that the sensitivity of MY09/11-based assays was greater
for HPV 52 than GP5+/6+. There were no diﬀerences in
DNA detection for HPV 16, 18, 33, and 45 across diﬀerent
laboratories and assays [14]. Conversely, HPV 31, 35, 52,
and 6 did show assay diﬀerences in sensitivity and speciﬁcity
that should be considered when interpreting results from
diﬀerent laboratories [15]. Taniyama et al. pointed out the
same issue. They reported that the prevalence of HPV 52
infection may have been underestimated in previous studies
and the HPV 52 type could be more prevalent than what
has been reported in Asia, and as a result, the vaccination
against HPV 16 and 18 would be less eﬀective in Asia than
that expected in the West [16].
Clinical studies of HPV vaccines have demonstrated
close to 100% protection against HPV 16- and HPV 18-
related infections and diseases [17–19], implying potential6 Pathology Research International
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Figure 2: Prevalence of HPV and cytological ﬁndings by age.
cross-protection against HPV 31, 33, 45, 52, and 58 [18,
19]. Paavonen et al. assessed the HPV 16 and 18 vaccine
eﬃcacy for young women aged 15–25 years. They reported
that vaccine eﬃcacy against CIN2 or more (CIN2+) with
a composite endpoint of the most prevalent nonvaccine
oncogenic HPV types (i.e., 31, 33, 45, 52, and 58) in invasive
cervical cancer was greater than 50%. Tangible data of
vaccine eﬃcacy for CIN2+ against HPV 31,33, 45, 52, and
58 was 92.0%, 51.9%, 100%, 14.3%, and 64.5% respectively.
Although signiﬁcant vaccine eﬃcacy against HPV 31, 33,
and 45 was noted for 6-month persistent infections, no
signiﬁcant vaccine eﬃcacy against HPV 52 and 58 was
observed for 6-month persistent infections or 12-month
persistent infections and CIN2+. This result supports the
robustness of cross-protection against HPV types 31, 33, and
45, and vaccine eﬃcacy against HPV 52 and 58 has a certain
level of eﬀect [20].
We also need to focus on HPV prevalence by age. HPV
infectionwasmostfrequentlydetectedinyoungwomenaged
15–25 years, and a second peak was observed in women
aged 55 years or older, which is also consistent with results
from African, American, and European populations [21],
although the reason for the second peak is unknown [3].
M a j o rr i s kf a c t o r sf o rc e r v i c a lc a n c e ra r eh i g h - r i s kH P V
infection and persistent infection. One of the persistent risk
factors is old age. In our analysis, older women have a
high detection rate of HPV 52 and 58. Lindau et al., who
estimated the prevalence and genotypes of high-risk HPV
among women aged 57–85, also reported that the prevalence
of HPV 52 (12.9%) and 58 (12.5%) was higher than that of
HPV 16 (9.7%) [22].
In the future, HPV typing in conjunction with cervical
cytology testing could be used for uterine cancer screening
or in a follow-up program after conservative treatment
of uterine cervical lesions since around 10% of NILM
patients were HPV-positive. The natural history of HPV
52 and 58 is still unknown. Even after current widespread
HPV vaccination, cross-protection against HPV 52 and
58 after the age of 30 remains incompletely understood,
so attention should be paid to geographical distribution
and causal signiﬁcance of HPV types for uterine cervical
lesions. A more sensitive and accurate method for HPV
typingwithcorrespondingclinicalresearchwillpermitbetter
understanding of the eﬀects of the HPV genotype.
5.Conclusions
In Japan, as a cause of abnormal cervical cytology, HPV
52 and HPV 58 cannot be ignored. Even after current
widespread HPV vaccination, smear abnormalities focusing
on HPV 52 and HPV 58 infection should be carefully
followed up.
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